Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Biosimilars Rheumatology Roundup: June 2025

July 01, 2025

The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

March 29th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Drs Lio, Botsoglou, and Alexrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

The Top 5 Biosimilar Articles for the Week of March 25

March 29th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 25, 2024.

Report on Part D Tiering Shows Low Coverage Rates for Biosimilars

March 27th 2024

By Skylar Jeremias

Article

The Association for Accessible Medicines’ report on Medicare Part D tiering revealed low coverage rates for insulin and adalimumab biosimilars across plans.

Switch to Biosimilar BAT1806/BIIB800 Maintains Efficacy, Safety in Patients With RA

March 26th 2024

By Cameron Santoro

Article

Switching to the biosimilar version of tocilizumab (BAT1806/BIIB800) showed similar effectiveness, safety, and tolerability compared with the original drug for patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate.

Annual STADA Report Shows Record Profit Growth for 2023

March 25th 2024

By Cameron Santoro

Article

Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.

Senators Reintroduce the Increasing Access to Biosimilars Act

March 25th 2024

By Skylar Jeremias

Article

Two senators reintroduce the Increasing Access to Biosimilars Act, a bipartisan bill aimed at boosting competition and encouraging providers to prescribe biosimilars, to Congress.

Antitrust Lawsuits on Increasing Biosimilar Accessibility

March 24th 2024

By Cameron Santoro

Video

Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering biosimilar access remains uncertain.

Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD

March 23rd 2024

By Deana Ferreri, PhD

Article

A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.

The Top 5 Biosimilar Articles for the Week of March 18

March 22nd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 18, 2024.

Sandoz Biosimilar Earnings Jump 15% in 2023

March 21st 2024

By Skylar Jeremias

Article

In its latest earnings report, Sandoz championed 7% growth overall throughout 2023, including a 15% spike in biosimilar revenues.